If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
577.50    5.50 (0.96%)
Bid:
577.00
Ask:
577.50
Spread: 0.50 (0.087%)
Market Cap: £1.56b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

AGM Statement

17 Mar 2017 07:00

RNS Number : 7511Z
Chemring Group PLC
17 March 2017
 

 

FOR IMMEDIATE RELEASE 17 MARCH 2017

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

Annual General Meeting - trading update for the four month period ended 26 February 2017

Chemring Group PLC today issues an update on current trading and outlook, to coincide with the Company's Annual General Meeting.

Current trading

The Group has started the year positively, continuing the momentum of the second half of last year. Order intake in the first four months of the year was in line with the Board's expectations at £127.4m (28 February 2016: £88.9m).

Revenue during the four month period to 26 February 2017 was £145.6m (28 February 2016: £106.5m), reflecting both the significant weakening of sterling and the fulfilment of contracts in the Energetics Systems division.

The order book at 26 February 2017 was £556.9m (28 February 2016: £596.3m, 31 October 2016: £592.9m), the reduction since 31 October 2016, half being attributable to the weaker dollar against sterling and half to stable operational performance resulting in some order backlog being cleared.

Balance sheet

Net debt at 26 February 2017 was £146.4m (28 February 2016: £141.4m, 31 October 2016: £87.6m). The increase in net debt since 31 October 2016 reflects the investment in working capital required to fund the execution of contracts in the Energetics division, which continue to perform well and, assuming an extension of the existing letter of credit is agreed, are expected to be strong contributors to 2017 performance. This investment is expected to be sustained at the half year, but partially reverse in the second half of the financial year.

Dividend

The Company announced on 19 January 2017 that, in view of the Group's improved trading performance for 2016, the Board intended to pay a final dividend of 1.3p in respect of the year ended 31 October 2016. This year's notice of AGM omitted the resolution seeking shareholder approval for the payment of a final dividend of 1.3p per ordinary share. Accordingly, the Board will, in accordance with its powers under the Company's articles of association, today declare a dividend in place of the proposed final dividend. The dividend will not require the approval of shareholders. The amount of this dividend shall be 1.3p per ordinary share. This dividend will be paid on 18 May 2017 to all shareholders who were on the Register of Members on 28 April 2017. The amount of the dividend and the timing of payment will therefore be the same as the final dividend previously proposed.

Outlook

The Board's expectations for trading for the full year remain unchanged. As expected, the seasonality of the business and customer requirements will mean that trading performance and cashflows will be weighted to the second half, but this is expected to be less pronounced than in the prior year.

Interim results for the six months ended 30 April 2017 will be announced on 22 June 2017.

- ENDS -

For further information:

Michael Flowers

Chief Executive, Chemring Group PLC

+44 (0)1794 833901

Andrew Lewis

Group Finance Director, Chemring Group PLC

+44 (0)1794 833901

Rupert Pittman

Group Director of Corporate Affairs, Chemring Group PLC

+44 (0)1794 833901

James White

MHP Communications

+44 (0)20 3128 8100

 

Cautionary statement

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

Notes to editors

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is now organised under three strategic product segments: Countermeasures, Sensors & Electronics, and Energetic Systems

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development, Chemring has the agility to rapidly react to urgent customer needs

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUNRKRBKAOAAR
Date   Source Headline
7th Mar 20167:00 amRNSAPPOINTMENT OF NON-EXECUTIVE DIRECTOR
1st Mar 20165:26 pmRNSCorrection Re Holding in Company
1st Mar 20161:24 pmRNSTotal Voting Rights
26th Feb 201610:23 amRNSHolding(s) in Company
24th Feb 20168:48 amRNSResult of Rump Placing
23rd Feb 20163:03 pmRNSResults of Rights Issue
23rd Feb 201612:40 pmRNSHolding(s) in Company
19th Feb 20163:13 pmRNSDirector/PDMR Shareholding
9th Feb 20168:07 amRNSAdmission of Nil Paid Rights
8th Feb 201611:52 amRNSResult of EGM
4th Feb 201611:26 amRNSDirector/PDMR Shareholding
4th Feb 201611:25 amRNSDirector/PDMR Shareholding
1st Feb 201611:18 amRNSTotal Voting Rights
27th Jan 20167:00 amRNSDirector/PDMR Shareholding
21st Jan 20163:30 pmRNSPublication of Prospectus
21st Jan 20167:00 amRNS£80.8 million Rights Issue
21st Jan 20167:00 amRNSFinal Results
20th Jan 20164:01 pmRNSDirector/PDMR Shareholding
4th Jan 201610:01 amRNSTotal Voting Rights
21st Dec 201511:19 amRNSBlocklisting Update
21st Dec 201511:17 amRNSBlocklisting Interim Review
1st Dec 20159:57 amRNSTotal Voting Rights
25th Nov 20157:00 amRNSPOST-CLOSE STATEMENT
2nd Nov 201511:21 amRNSHolding(s) in Company
27th Oct 20157:00 amRNSTrading Statement
1st Oct 201511:15 amRNSTotal Voting Rights
29th Sep 20152:25 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSTrading Update
1st Sep 20159:33 amRNSTotal Voting Rights
20th Aug 20153:01 pmRNSHolding(s) in Company
7th Aug 20151:56 pmRNSHolding(s) in Company
3rd Aug 20159:28 amRNSTotal Voting Rights
1st Jul 20152:47 pmRNSTotal Voting Rights
24th Jun 20155:26 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHalf Yearly Report
19th Jun 20158:55 amRNSBlocklisting Update
19th Jun 20157:00 amRNSBlocklisting Interim Review
11th Jun 201510:02 amRNSAdditional Listing
2nd Jun 20157:00 amRNSTotal Voting Rights
1st May 201512:01 pmRNSTotal Voting Rights
10th Apr 201511:59 amRNSTotal Voting Rights
19th Mar 20152:21 pmRNSResult of AGM
19th Mar 20157:00 amRNSAGM Statement
2nd Mar 20151:41 pmRNSTotal Voting Rights
2nd Feb 20151:16 pmRNSTotal Voting Rights
27th Jan 20154:10 pmRNSDirector/PDMR Shareholding
27th Jan 20154:09 pmRNSDirector/PDMR Shareholding
27th Jan 20154:08 pmRNSDirector/PDMR Shareholding
27th Jan 201512:25 pmRNSDirector/PDMR Shareholding
27th Jan 201512:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.